STOCK TITAN

[Form 4] SELECT MEDICAL HOLDINGS CORP Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Insider activity: Director Thomas Daniel filed Form 4 for Select Medical Holdings (SEM) disclosing a grant of 14,035 restricted shares on 07/29/2025 (transaction code “A”). The award carries a $0 purchase price and vests in full on 07/29/2026. Following the grant, Daniel directly owns 80,035 common shares; no derivative securities or sales were reported.

The filing represents routine director compensation and modestly increases insider ownership. No cash outlay, option exercises or open-market purchases occurred, so the transaction is unlikely to materially affect near-term supply-demand dynamics for SEM shares.

Attività degli insider: Il direttore Thomas Daniel ha presentato il Modulo 4 per Select Medical Holdings (SEM) dichiarando una concessione di 14.035 azioni vincolate il 29/07/2025 (codice transazione “A”). Il premio ha un prezzo di acquisto pari a $0 e matura completamente il 29/07/2026. Dopo la concessione, Daniel possiede direttamente 80.035 azioni ordinarie; non sono stati segnalati titoli derivati né vendite.

La comunicazione rappresenta una normale remunerazione per il direttore e aumenta modestamente la partecipazione degli insider. Non essendoci stati esborsi in contanti, esercizi di opzioni o acquisti sul mercato aperto, la transazione difficilmente influenzerà in modo significativo la dinamica domanda-offerta a breve termine delle azioni SEM.

Actividad de insiders: El director Thomas Daniel presentó el Formulario 4 para Select Medical Holdings (SEM) revelando una concesión de 14,035 acciones restringidas el 29/07/2025 (código de transacción “A”). La adjudicación tiene un precio de compra de $0 y se consolida completamente el 29/07/2026. Tras la concesión, Daniel posee directamente 80,035 acciones ordinarias; no se reportaron valores derivados ni ventas.

La presentación representa una compensación rutinaria para el director y aumenta modestamente la propiedad de los insiders. No hubo desembolsos en efectivo, ejercicios de opciones ni compras en el mercado abierto, por lo que la transacción probablemente no afectará materialmente la dinámica de oferta y demanda a corto plazo de las acciones de SEM.

내부자 거래 내역: 이사 토마스 다니엘은 Select Medical Holdings(SEM)에 대해 2025년 7월 29일에 14,035주의 제한 주식 부여를 신고하는 Form 4를 제출했습니다(거래 코드 “A”). 이 보상은 구매 가격이 $0이며 2026년 7월 29일에 전액 취득됩니다. 부여 후 다니엘은 직접 80,035주의 보통주를 보유하고 있으며, 파생 증권이나 매도 내역은 보고되지 않았습니다.

이번 신고는 이사의 정기 보상에 해당하며 내부자 지분을 소폭 증가시킵니다. 현금 지출, 옵션 행사 또는 공개 시장 매수는 없었으므로 이번 거래가 단기적으로 SEM 주식의 수급에 큰 영향을 미칠 가능성은 낮습니다.

Activité des initiés : Le directeur Thomas Daniel a déposé le formulaire 4 pour Select Medical Holdings (SEM), révélant une attribution de 14 035 actions restreintes le 29/07/2025 (code de transaction « A »). Cette attribution est à prix d’achat nul et devient entièrement acquise le 29/07/2026. Après cette attribution, Daniel détient directement 80 035 actions ordinaires ; aucun titre dérivé ni vente n’a été signalé.

Cette déclaration correspond à une rémunération habituelle du directeur et augmente modestement la détention d’initiés. Aucun décaissement en espèces, exercice d’options ou achat sur le marché ouvert n’a eu lieu, si bien que cette transaction est peu susceptible d’affecter significativement l’équilibre offre-demande à court terme des actions SEM.

Insider-Aktivitäten: Direktor Thomas Daniel reichte am 29.07.2025 ein Formular 4 für Select Medical Holdings (SEM) ein, in dem er eine Gewährung von 14.035 eingeschränkten Aktien (Transaktionscode „A“) offenlegte. Die Zuteilung hat einen Kaufpreis von 0 $ und fällt vollständig am 29.07.2026 frei. Nach der Gewährung besitzt Daniel direkt 80.035 Stammaktien; Derivate oder Verkäufe wurden nicht gemeldet.

Die Meldung stellt eine routinemäßige Vergütung des Direktors dar und erhöht den Insider-Besitz geringfügig. Da keine Barauslagen, Optionsausübungen oder Käufe am offenen Markt stattfanden, wird die Transaktion die kurzfristigen Angebots-Nachfrage-Dynamiken der SEM-Aktien voraussichtlich nicht wesentlich beeinflussen.

Positive
  • Increased insider ownership: Director’s stake rises by 14,035 shares, strengthening alignment with shareholders.
Negative
  • No open-market purchase: Shares were granted at $0, so the filing lacks the bullish signal of a cash-backed buy.
  • Minor dilution: Issuance of new shares, though immaterial relative to total outstanding, is incrementally dilutive.

Insights

TL;DR: Routine restricted-stock grant; immaterial dilution but slightly better alignment of director and shareholder interests.

The Form 4 shows a typical board compensation grant rather than an open-market buy, so signalling value is limited. The additional 14,035 shares lift Daniel’s direct stake to 80,035, a ~21% increase in his holdings but negligible versus SEM’s ~128 million shares outstanding. Because the shares were issued at no cost and vest over one year, they contribute minor dilution yet improve incentive alignment in 2026. Overall impact on valuation, liquidity and governance is neutral.

Attività degli insider: Il direttore Thomas Daniel ha presentato il Modulo 4 per Select Medical Holdings (SEM) dichiarando una concessione di 14.035 azioni vincolate il 29/07/2025 (codice transazione “A”). Il premio ha un prezzo di acquisto pari a $0 e matura completamente il 29/07/2026. Dopo la concessione, Daniel possiede direttamente 80.035 azioni ordinarie; non sono stati segnalati titoli derivati né vendite.

La comunicazione rappresenta una normale remunerazione per il direttore e aumenta modestamente la partecipazione degli insider. Non essendoci stati esborsi in contanti, esercizi di opzioni o acquisti sul mercato aperto, la transazione difficilmente influenzerà in modo significativo la dinamica domanda-offerta a breve termine delle azioni SEM.

Actividad de insiders: El director Thomas Daniel presentó el Formulario 4 para Select Medical Holdings (SEM) revelando una concesión de 14,035 acciones restringidas el 29/07/2025 (código de transacción “A”). La adjudicación tiene un precio de compra de $0 y se consolida completamente el 29/07/2026. Tras la concesión, Daniel posee directamente 80,035 acciones ordinarias; no se reportaron valores derivados ni ventas.

La presentación representa una compensación rutinaria para el director y aumenta modestamente la propiedad de los insiders. No hubo desembolsos en efectivo, ejercicios de opciones ni compras en el mercado abierto, por lo que la transacción probablemente no afectará materialmente la dinámica de oferta y demanda a corto plazo de las acciones de SEM.

내부자 거래 내역: 이사 토마스 다니엘은 Select Medical Holdings(SEM)에 대해 2025년 7월 29일에 14,035주의 제한 주식 부여를 신고하는 Form 4를 제출했습니다(거래 코드 “A”). 이 보상은 구매 가격이 $0이며 2026년 7월 29일에 전액 취득됩니다. 부여 후 다니엘은 직접 80,035주의 보통주를 보유하고 있으며, 파생 증권이나 매도 내역은 보고되지 않았습니다.

이번 신고는 이사의 정기 보상에 해당하며 내부자 지분을 소폭 증가시킵니다. 현금 지출, 옵션 행사 또는 공개 시장 매수는 없었으므로 이번 거래가 단기적으로 SEM 주식의 수급에 큰 영향을 미칠 가능성은 낮습니다.

Activité des initiés : Le directeur Thomas Daniel a déposé le formulaire 4 pour Select Medical Holdings (SEM), révélant une attribution de 14 035 actions restreintes le 29/07/2025 (code de transaction « A »). Cette attribution est à prix d’achat nul et devient entièrement acquise le 29/07/2026. Après cette attribution, Daniel détient directement 80 035 actions ordinaires ; aucun titre dérivé ni vente n’a été signalé.

Cette déclaration correspond à une rémunération habituelle du directeur et augmente modestement la détention d’initiés. Aucun décaissement en espèces, exercice d’options ou achat sur le marché ouvert n’a eu lieu, si bien que cette transaction est peu susceptible d’affecter significativement l’équilibre offre-demande à court terme des actions SEM.

Insider-Aktivitäten: Direktor Thomas Daniel reichte am 29.07.2025 ein Formular 4 für Select Medical Holdings (SEM) ein, in dem er eine Gewährung von 14.035 eingeschränkten Aktien (Transaktionscode „A“) offenlegte. Die Zuteilung hat einen Kaufpreis von 0 $ und fällt vollständig am 29.07.2026 frei. Nach der Gewährung besitzt Daniel direkt 80.035 Stammaktien; Derivate oder Verkäufe wurden nicht gemeldet.

Die Meldung stellt eine routinemäßige Vergütung des Direktors dar und erhöht den Insider-Besitz geringfügig. Da keine Barauslagen, Optionsausübungen oder Käufe am offenen Markt stattfanden, wird die Transaktion die kurzfristigen Angebots-Nachfrage-Dynamiken der SEM-Aktien voraussichtlich nicht wesentlich beeinflussen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Thomas Daniel

(Last) (First) (Middle)
C/O SELECT MEDICAL CORPORATION
4714 GETTYSBURG ROAD

(Street)
MECHANICSBURG PA 17055

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
SELECT MEDICAL HOLDINGS CORP [ SEM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/29/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/29/2025 A(1) 14,035 A $0 80,035 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Grant of restricted stock which, subject to certain exceptions, will vest in full on July 29, 2026, the first anniversary of the grant date.
/s/ Michael E. Tarvin, Attorney-in-Fact 07/31/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did SEM report on 07/29/2025?

Director Thomas Daniel received 14,035 restricted shares as compensation, disclosed in a Form 4.

At what price were the shares acquired?

The restricted stock was granted at $0 cost; no cash changed hands.

When will the granted shares vest?

All 14,035 shares vest on 07/29/2026, one year after the grant date.

How many SEM shares does the director now own?

After the grant, Daniel directly owns 80,035 common shares.

Did the filing include any stock sales or option exercises?

No, the Form 4 reported no sales or derivative transactions.
Select Medical

NYSE:SEM

SEM Rankings

SEM Latest News

SEM Latest SEC Filings

SEM Stock Data

1.83B
110.06M
14.6%
83.81%
3.47%
Medical Care Facilities
Services-hospitals
Link
United States
MECHANICSBURG